JP2014501284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501284A5 JP2014501284A5 JP2013547684A JP2013547684A JP2014501284A5 JP 2014501284 A5 JP2014501284 A5 JP 2014501284A5 JP 2013547684 A JP2013547684 A JP 2013547684A JP 2013547684 A JP2013547684 A JP 2013547684A JP 2014501284 A5 JP2014501284 A5 JP 2014501284A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- composition according
- items
- composition
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 216
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 39
- 229940111134 coxibs Drugs 0.000 claims description 38
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 38
- 239000002840 nitric oxide donor Substances 0.000 claims description 30
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 28
- 229920000136 polysorbate Polymers 0.000 claims description 23
- 229950008882 polysorbate Drugs 0.000 claims description 23
- 229920000642 polymer Polymers 0.000 claims description 22
- 230000000087 stabilizing effect Effects 0.000 claims description 21
- 239000004094 surface-active agent Substances 0.000 claims description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 14
- 210000003491 skin Anatomy 0.000 claims description 13
- 230000000699 topical effect Effects 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000000230 xanthan gum Substances 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- 229940082509 xanthan gum Drugs 0.000 claims description 6
- 235000010493 xanthan gum Nutrition 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 5
- 229930064664 L-arginine Natural products 0.000 claims description 5
- 235000014852 L-arginine Nutrition 0.000 claims description 5
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 235000019743 Choline chloride Nutrition 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 4
- 229960003178 choline chloride Drugs 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 229940068977 polysorbate 20 Drugs 0.000 claims description 4
- 210000000434 stratum corneum Anatomy 0.000 claims description 4
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 3
- 229960000590 celecoxib Drugs 0.000 claims description 3
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 3
- 229960000371 rofecoxib Drugs 0.000 claims description 3
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical group C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 description 21
- 239000003981 vehicle Substances 0.000 description 9
- 235000019901 KELTROL® Nutrition 0.000 description 8
- 150000003841 chloride salts Chemical class 0.000 description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- 229940075529 glyceryl stearate Drugs 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical group CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- HGASFNYMVGEKTF-UHFFFAOYSA-N octan-1-ol;hydrate Chemical compound O.CCCCCCCCO HGASFNYMVGEKTF-UHFFFAOYSA-N 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061428213P | 2010-12-29 | 2010-12-29 | |
| US201061428057P | 2010-12-29 | 2010-12-29 | |
| US61/428,213 | 2010-12-29 | ||
| US61/428,057 | 2010-12-29 | ||
| PCT/US2011/067990 WO2012092525A1 (en) | 2010-12-29 | 2011-12-29 | Cox-2 inhibitors and related compounds, and systems and methods for delivery thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015239307A Division JP2016033168A (ja) | 2010-12-29 | 2015-12-08 | Ｃｏｘ−２阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014501284A JP2014501284A (ja) | 2014-01-20 |
| JP2014501284A5 true JP2014501284A5 (enExample) | 2015-02-19 |
Family
ID=46383540
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013547684A Pending JP2014501284A (ja) | 2010-12-29 | 2011-12-29 | Ｃｏｘ−２阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法 |
| JP2015239307A Pending JP2016033168A (ja) | 2010-12-29 | 2015-12-08 | Ｃｏｘ−２阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015239307A Pending JP2016033168A (ja) | 2010-12-29 | 2015-12-08 | Ｃｏｘ−２阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140004177A1 (enExample) |
| EP (1) | EP2658553A4 (enExample) |
| JP (2) | JP2014501284A (enExample) |
| CN (1) | CN103442722A (enExample) |
| WO (1) | WO2012092525A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629384B2 (en) * | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
| US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
| JP2007532697A (ja) * | 2004-04-19 | 2007-11-15 | ストラテジック サイエンス アンド テクノロジーズ， エルエルシー | 局所的血流増大の有益な効果 |
| US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| EP2445493A1 (en) | 2009-06-24 | 2012-05-02 | Strategic Science & Technologies, LLC | Topical composition containing naproxen |
| US12138268B2 (en) | 2009-06-24 | 2024-11-12 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| CN102481275B (zh) | 2009-06-24 | 2014-07-23 | 战略科学技术有限公司 | 含有布洛芬的表面组合物 |
| CN103442723A (zh) | 2010-12-29 | 2013-12-11 | 战略科学与技术有限责任公司 | 治疗变态反应和其它适应症的系统和方法 |
| EP2658551B1 (en) | 2010-12-29 | 2020-07-01 | Strategic Science & Technologies, LLC | Treatment of erectile dysfunction and other indications |
| EP2968124A1 (en) * | 2013-03-15 | 2016-01-20 | Strategic Science & Technologies, LLC | Transdermal formulations of fluticasone |
| WO2016112201A1 (en) * | 2015-01-07 | 2016-07-14 | Strategic Science & Technologies, Llc | Techniques and systems for transdermal delivery involving treatment of psoriasis, skin cancer, and other indications |
| US9949915B2 (en) | 2016-06-10 | 2018-04-24 | Clarity Cosmetics Inc. | Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use |
| US12440438B2 (en) * | 2019-07-22 | 2025-10-14 | Novilla Pharmaceuticals, Inc. | Method of remotely controlling pain |
| CA3164165A1 (en) * | 2020-01-10 | 2021-07-15 | Robert Bruce Register | Topical compositions containing rofecoxib and methods of making and using the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090105336A1 (en) * | 2004-04-19 | 2009-04-23 | Strategic Science & Technologies, Llc | Beneficial Effects of Increasing Local Blood Flow |
| JP2007532697A (ja) * | 2004-04-19 | 2007-11-15 | ストラテジック サイエンス アンド テクノロジーズ， エルエルシー | 局所的血流増大の有益な効果 |
| US8454945B2 (en) * | 2007-03-22 | 2013-06-04 | Berg Pharma Llc | Topical formulations having enhanced bioavailability |
| US20100099766A1 (en) * | 2008-10-16 | 2010-04-22 | Novartis Ag | Topical NSAID compositions having sensate component |
| CN102481275B (zh) * | 2009-06-24 | 2014-07-23 | 战略科学技术有限公司 | 含有布洛芬的表面组合物 |
-
2011
- 2011-12-29 EP EP11854161.4A patent/EP2658553A4/en not_active Withdrawn
- 2011-12-29 CN CN2011800686152A patent/CN103442722A/zh active Pending
- 2011-12-29 WO PCT/US2011/067990 patent/WO2012092525A1/en not_active Ceased
- 2011-12-29 US US13/977,562 patent/US20140004177A1/en not_active Abandoned
- 2011-12-29 JP JP2013547684A patent/JP2014501284A/ja active Pending
-
2015
- 2015-12-08 JP JP2015239307A patent/JP2016033168A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014504592A5 (enExample) | ||
| JP2014501286A5 (enExample) | ||
| JP2014501283A5 (enExample) | ||
| JP2014501285A5 (enExample) | ||
| RU2012102284A (ru) | Топическая композиция, содержащая ибупрофен | |
| JP2012062328A5 (enExample) | ||
| AU2006339841B2 (en) | Pharmaceutical composition for external use | |
| JP6955648B2 (ja) | 異常炎症反応に関連する状態を処置するための方法および組成物 | |
| JP2016135812A5 (enExample) | ||
| EP2158907B1 (en) | Topical administration of arginine for pain treatment | |
| HRP20201512T1 (hr) | Liječenje erektilne disfunkcije i drugih indikacija | |
| JP2022174292A5 (enExample) | ||
| JP5674020B2 (ja) | 転写因子デコイを有効成分とする外用剤組成物 | |
| RU2007119380A (ru) | Косметические продукты, предназначенные для ухода за собой, включающие соли дигидроксипропилтри (c1-c3алкил) аммония | |
| CN103442722A (zh) | Cox-2抑制剂和相关的化合物、及其递送系统和方法 | |
| WO2007102243A1 (ja) | 外用の医薬組成物 | |
| JP2012197300A5 (enExample) | ||
| MX2015007785A (es) | Productos antitranspirantes con proteinas y sales antitranspirantes. | |
| ES2244373T3 (es) | Emplasto de uso topico que contiene heparina y diclofenaco. | |
| EA200901112A1 (ru) | Жидкие композиции, образующие дермальные пленки, для введения лекарственных препаратов в кожу | |
| CN103442723A (zh) | 治疗变态反应和其它适应症的系统和方法 | |
| JP2012508251A5 (enExample) | ||
| WO2016178053A1 (en) | Compositions for the treatment of epistaxis | |
| US6680073B1 (en) | Composition and method for the treatment of onychomycosis in animals | |
| BR112017012807B1 (pt) | Composição para higiene bucal e uso de um complexo solúvel de polifosfato de zinco na preparação da mesma |